Annual CFO
-$27.00 M
+$159.99 M+85.56%
December 31, 2023
Summary
- As of February 8, 2025, TBPH annual cash flow from operations is -$27.00 million, with the most recent change of +$159.99 million (+85.56%) on December 31, 2023.
- During the last 3 years, TBPH annual CFO has risen by +$223.41 million (+89.22%).
- TBPH annual CFO is now at all-time high.
Performance
TBPH Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$5.20 M
-$781.00 K-17.69%
September 30, 2024
Summary
- As of February 8, 2025, TBPH quarterly cash flow from operations is -$5.20 million, with the most recent change of -$781.00 thousand (-17.69%) on September 30, 2024.
- Over the past year, TBPH quarterly CFO has dropped by -$2.71 million (-109.01%).
- TBPH quarterly CFO is now -110.43% below its all-time high of $49.83 million, reached on March 31, 2018.
Performance
TBPH Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$11.49 M
-$2.71 M-30.88%
September 30, 2024
Summary
- As of February 8, 2025, TBPH TTM cash flow from operations is -$11.49 million, with the most recent change of -$2.71 million (-30.88%) on September 30, 2024.
- Over the past year, TBPH TTM CFO has increased by +$138.71 million (+92.35%).
- TBPH TTM CFO is now -30.88% below its all-time high of -$8.78 million, reached on June 30, 2024.
Performance
TBPH TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
TBPH Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +85.6% | -109.0% | +92.3% |
| 3 y3 years | +89.2% | +88.6% | +95.0% |
| 5 y5 years | +76.1% | +92.0% | +95.4% |
TBPH Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +87.0% | -508.4% | +95.8% | -30.9% | +94.5% |
| 5 y | 5-year | at high | +89.2% | -508.4% | +95.8% | -30.9% | +95.7% |
| alltime | all time | at high | +89.2% | -110.4% | +95.8% | -30.9% | +95.7% |
Theravance Biopharma Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$5.20 M(+17.7%) | -$11.49 M(+30.9%) |
| Jun 2024 | - | -$4.42 M(+332.0%) | -$8.78 M(-47.7%) |
| Mar 2024 | - | -$1.02 M(+19.7%) | -$16.80 M(-37.8%) |
| Dec 2023 | -$27.00 M(-85.6%) | -$854.00 K(-65.6%) | -$27.00 M(-82.0%) |
| Sep 2023 | - | -$2.49 M(-80.0%) | -$150.20 M(-11.6%) |
| Jun 2023 | - | -$12.44 M(+10.8%) | -$169.85 M(-1.3%) |
| Mar 2023 | - | -$11.22 M(-91.0%) | -$172.14 M(-7.9%) |
| Dec 2022 | -$186.99 M(-10.0%) | -$124.06 M(+460.4%) | -$186.99 M(+77.5%) |
| Sep 2022 | - | -$22.14 M(+50.3%) | -$105.37 M(-18.1%) |
| Jun 2022 | - | -$14.73 M(-43.5%) | -$128.68 M(-21.6%) |
| Mar 2022 | - | -$26.07 M(-38.6%) | -$164.06 M(-21.1%) |
| Dec 2021 | -$207.86 M(-17.0%) | -$42.43 M(-6.6%) | -$207.86 M(-9.8%) |
| Sep 2021 | - | -$45.45 M(-9.3%) | -$230.35 M(-12.1%) |
| Jun 2021 | - | -$50.11 M(-28.3%) | -$261.93 M(-1.2%) |
| Mar 2021 | - | -$69.86 M(+7.6%) | -$265.17 M(+5.9%) |
| Dec 2020 | -$250.40 M(+5.1%) | -$64.92 M(-15.7%) | -$250.40 M(+0.2%) |
| Sep 2020 | - | -$77.03 M(+44.4%) | -$249.83 M(+14.9%) |
| Jun 2020 | - | -$53.35 M(-3.2%) | -$217.42 M(+2.5%) |
| Mar 2020 | - | -$55.10 M(-14.4%) | -$212.10 M(-11.0%) |
| Dec 2019 | -$238.20 M(+111.0%) | -$64.35 M(+44.2%) | -$238.20 M(+5.4%) |
| Sep 2019 | - | -$44.62 M(-7.1%) | -$226.02 M(-1.9%) |
| Jun 2019 | - | -$48.03 M(-40.8%) | -$230.38 M(-5.5%) |
| Mar 2019 | - | -$81.19 M(+55.6%) | -$243.88 M(+116.1%) |
| Dec 2018 | -$112.87 M | -$52.18 M(+6.5%) | -$112.87 M(+7.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$48.98 M(-20.4%) | -$104.89 M(-11.3%) |
| Jun 2018 | - | -$61.54 M(-223.5%) | -$118.21 M(+16.8%) |
| Mar 2018 | - | $49.83 M(-212.7%) | -$101.20 M(-49.7%) |
| Dec 2017 | -$201.05 M(+103.1%) | -$44.20 M(-29.0%) | -$201.05 M(+8.7%) |
| Sep 2017 | - | -$62.30 M(+39.9%) | -$184.96 M(+36.9%) |
| Jun 2017 | - | -$44.52 M(-11.0%) | -$135.10 M(+10.1%) |
| Mar 2017 | - | -$50.03 M(+77.9%) | -$122.71 M(+24.0%) |
| Dec 2016 | -$98.99 M(-41.4%) | -$28.11 M(+126.1%) | -$98.99 M(-5.4%) |
| Sep 2016 | - | -$12.43 M(-61.3%) | -$104.62 M(-15.7%) |
| Jun 2016 | - | -$32.13 M(+22.1%) | -$124.17 M(-10.4%) |
| Mar 2016 | - | -$26.31 M(-22.0%) | -$138.65 M(-17.9%) |
| Dec 2015 | -$168.86 M(-3.6%) | -$33.75 M(+5.5%) | -$168.86 M(-4.9%) |
| Sep 2015 | - | -$31.98 M(-31.4%) | -$177.65 M(-2.4%) |
| Jun 2015 | - | -$46.61 M(-17.5%) | -$182.04 M(-2.6%) |
| Mar 2015 | - | -$56.51 M(+32.9%) | -$186.87 M(+6.7%) |
| Dec 2014 | -$175.16 M(+44.8%) | -$42.54 M(+16.9%) | -$175.16 M(+4.4%) |
| Sep 2014 | - | -$36.38 M(-29.3%) | -$167.80 M(+2.1%) |
| Jun 2014 | - | -$51.44 M(+14.8%) | -$164.36 M(+19.7%) |
| Mar 2014 | - | -$44.80 M(+27.3%) | -$137.27 M(+13.5%) |
| Dec 2013 | -$120.96 M(+1.6%) | -$35.19 M(+6.8%) | -$120.96 M(+41.0%) |
| Sep 2013 | - | -$32.94 M(+35.3%) | -$85.77 M(+62.3%) |
| Jun 2013 | - | -$24.34 M(-14.6%) | -$52.84 M(+85.4%) |
| Mar 2013 | - | -$28.49 M | -$28.49 M |
| Dec 2012 | -$119.11 M | - | - |
FAQ
- What is Theravance Biopharma annual cash flow from operations?
- What is the all time high annual CFO for Theravance Biopharma?
- What is Theravance Biopharma annual CFO year-on-year change?
- What is Theravance Biopharma quarterly cash flow from operations?
- What is the all time high quarterly CFO for Theravance Biopharma?
- What is Theravance Biopharma quarterly CFO year-on-year change?
- What is Theravance Biopharma TTM cash flow from operations?
- What is the all time high TTM CFO for Theravance Biopharma?
- What is Theravance Biopharma TTM CFO year-on-year change?
What is Theravance Biopharma annual cash flow from operations?
The current annual CFO of TBPH is -$27.00 M
What is the all time high annual CFO for Theravance Biopharma?
Theravance Biopharma all-time high annual cash flow from operations is -$27.00 M
What is Theravance Biopharma annual CFO year-on-year change?
Over the past year, TBPH annual cash flow from operations has changed by +$159.99 M (+85.56%)
What is Theravance Biopharma quarterly cash flow from operations?
The current quarterly CFO of TBPH is -$5.20 M
What is the all time high quarterly CFO for Theravance Biopharma?
Theravance Biopharma all-time high quarterly cash flow from operations is $49.83 M
What is Theravance Biopharma quarterly CFO year-on-year change?
Over the past year, TBPH quarterly cash flow from operations has changed by -$2.71 M (-109.01%)
What is Theravance Biopharma TTM cash flow from operations?
The current TTM CFO of TBPH is -$11.49 M
What is the all time high TTM CFO for Theravance Biopharma?
Theravance Biopharma all-time high TTM cash flow from operations is -$8.78 M
What is Theravance Biopharma TTM CFO year-on-year change?
Over the past year, TBPH TTM cash flow from operations has changed by +$138.71 M (+92.35%)